Hengrui Medicine: SHR-1049 Injection approved for clinical trial, no similar drugs approved for marketing at home and abroad.

Hengrui Pharmaceuticals announced that the company has recently received the approval and issuance of the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for SHR-1049 injection, allowing the drug to conduct clinical trials as a single agent in late-stage solid tumors. SHR-1049 injection is an innovative anti-tumor drug independently developed by the company, intended for the treatment of late-stage solid tumors. According to the investigation, there are currently no similar drugs approved for marketing domestically or internationally. As of now, the total research and development investment for the SHR-1049 injection project is approximately 26 million yuan.